This article featuring Alkermes' Chief Medical Officer, Craig Hopkinson, M.D., originally appeared in PharmaVoice in July 2022. In November 2023, Alkermes completed the separation of its oncology business into Mural Oncology plc, a new, independent, publicly traded company. Visit www.muraloncology.com to learn more.
Oncology research is progressing at a rapid clip, giving new hope to patients who once lacked options. However, gaps still remain. Immunotherapies, in particular, have propelled cancer treatment forward greatly — but not all patients can benefit from them. Hear how Alkermes is looking to fill some of those gaps by investigating potential new therapies for patients with challenging cancers and few treatment options.